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Cancer is an evolutionary phenomenon. Development and progression of cancer 
involves genetic instability and a complex clonal evolution process, which 
contributes to genetic and phenotypic heterogeneity. Advent of next-generation 
sequencing technologies has enabled in-depth interrogation of cancer genomes 
resulting in unraveling of the complexity of genomic heterogeneity and evolution 
in detail. Studies on relapsed and metastatic patients have revealed that subclones 
present at low-frequency at diagnosis could lead to relapse or seeding of distant 
metastatic clones, underscoring the importance of detecting rare subclones early 
on.  
 
The dynamic nature of clonal evolution and heterogeneity further adds to the 
complexity of treating cancers and difficulty in achieving long-term remissions. 
Tumor heterogeneity should be taken into account in developing new therapeutic 
strategies to target cancer at the subclone level and pre-emptively block the 
emergence of rare subclones that could lead to relapse. Therefore, as part of our 
individualized systems medicine program, we developed methods to interrogate 
spatial and temporal heterogeneity and evolution of cancer subclones to delineate 
the impact of therapy on them. 
 
In study I, we monitored responses of chemo and targeted therapies at leukemic 
cell subclones in chemorefractory acute myeloid leukemia. We performed 
exome-sequencing analysis of serial samples acquired from diagnosis to later 
relapses from the 13 AML patients.  In order to extend our understanding of 
clonal composition to include low-frequency subclones (< 10% frequency), we 
developed unique molecular identifier based ultra-deep amplicon sequencing 
approach to enhance rare variant detection. Statistical methods to interpret 
response of subclonal mutations to therapy from longitudinally acquired samples 
were employed to gain mechanistic insights on therapy response and resistance.  
 
In study II, we interrogated if genetic heterogeneity exists between multiple bone 
marrow compartments in AML patients. Numerous recent studies have reported 
on the extent of intra-tumoral heterogeneity in solid tumors, however very little 
information is available on its role in AML. Therefore, we acquired biopsies of 
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three anatomically distinct bone marrow compartments: corpus sternum, right 
and left iliac crest from two AML patients. Based on phylogenetic analysis of 
mutations identified from exome-sequencing data we reconstructed the cancer 
cell lineage from early ancestral cell to later diversification of subclones to 
distinct bone marrow compartments in individual patients. Although we did not 
identify subclonal mutations specific to a bone marrow site, we observed 
significant variance in subclonal frequencies between the bone marrow 
compartments and could interpret the genetic interconnection between the 
compartments.  
 
In study III, we integrated intra-tumor genomic heterogeneity with drug response 
heterogeneity in renal cell carcinoma to understand the impact of the cancer 
heterogeneity and evolution on variability in drug responsiveness. We developed 
patient derived cell culture models from primary and metastatic tumor tissues of 
four renal cell carcinoma patients for the study. Based on phylogenetic analysis 
of somatic mutations in tumor tissue and patient-derived cell culture models we 
inferred i) how representative the models are of the originating tumor tissues, ii) 
evolution and divergence of subclones in tumor tissues and models and, iii) the 
drug sensitivity and resistance profiles of each patient-derived cell culture model 
and variability of drug response between individual subclones. 
 
Taken together, we have developed methods to comprehensively study subclonal 
heterogeneity, subclonal-level responses to chemo and targeted drugs and 
integrated genetic heterogeneity with drug response profiles in a personalized 
medicine setting. The methods showcased in our studies are applicable to all 
cancers and can be tailored for longitudinal and spatial sampling strategy of 
tumors during the disease course. We believe that understanding of subclonal 
evolution and heterogeneity will provide basis for devising better combinatorial 
strategies to prevent future relapses to achieve better remission rates by targeting 




Cancer is not a singular disease but a phenomenon of accelerated evolution that 
continually changes the cancer genotype. New mutational events lead to 
evolution of cancer cells under selective pressure of the host and tumor 
microenvironment or cancer treatment. Treatment of cancer with 
chemotherapeutics, especially genotoxic drugs like alkylating agents not just 
eradicate major cancer clones but unleash additional mutations and a 
heterogeneous drug resistant cancer cell population. As a consequence of the 
resulting heterogeneity, cancer cells undergo evolutionary selections leading to 
emergence of drug resistant subclones and subsequent re-emergence of cancer.  
To understand the evolutionary nature of cancer and the impact of various factors 
on clonal selection, it is pertinent to obtain and analyze sequential cancer samples 
from diagnosis to eventual disease progression and therapy.  
 
The “concept of cure” in cancer was actualized in early 1960’s when significant 
remissions and long-term progression free survival were achieved using 
chemotherapeutics.1 Chemotherapy has been very effective and achieved 
significant “cures” in terms of progression-free survival in a subset of cancers 
such as paediatric acute leukemias, Burkitt’s lymphoma and in solid tumors such 
as testicular cancer, non-small cell lung cancer and subtypes of breast cancers.1-6 
Although, the overall contribution of cytotoxic therapy to progression-free 
survival remained at a modest 2.1% in adult cancer malignancies.2 In AML, 
chemotherapy is successful in achieving remissions in younger (60-80%) and 
older (60%) patients. Although 85% of older patients relapse within 2-3 years.7,8 
Relapse in cancer can be caused due to drug resistance, heterogeneity and 
selective pressure induced by therapy resulting in clonal evolution.9,10  
 
In late 90’s, a new generation of ‘targeted therapies’ designed to specifically 
target key molecular mechanisms involved in tumor initiation or growth 
emerged. The aim was to design drugs with high specificity and low toxicity. 
Discovery of BCR-ABL inhibitor (Gleevec) for treatment of chronic 
myelogenous leukemia (CML) heralded the beginning of biomarker based drug 
discovery for the next few decades.11 With the completion of human genome 
project and advent of new sequencing technologies,  extensive molecular 
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characterization of tumors became possible and resulted in designing of many 
new targeted therapies. Although kinase inhibitors which constitute majority of 
the targeted inhibitors, showed effect in cancers driven by single mutations in 
defined kinase-pathways, the magnitude of response in other cancers has been 
more limited. Cancers initially responding to targeted inhibitors relapsed due to 
positive selection of intrinsic drug-resistant cell clones or emergence of drug 
resistant subclones as a consequence of therapy. 9,12,13  
 
In most of the common hematological and solid tumors, targeted therapies have 
not resulted in a dramatic progress in long term remissions and cancer cures as 
was expected. This underscores the importance of the evolutionary aspect in 
cancer that heterogeneous tumors are hard to eradicate. Therefore, understanding 
of cancer evolutionary processes is required to make progress in managing 
cancer, if not for curing it. Recent advances in sequencing of sequential samples 
from hematological and solid tumors have shed light on cancer evolution and the 
underlying inter- and intra-tumor heterogeneity, thereby reshaping our thinking 
of cancer as even more complex and dynamic disease than earlier thought. 
 
The difficulties in introducing ‘one drug for all patients’ concept have led to the 
consideration of treating cancer at a personalized level in the hope of achieving 
long-term remissions by designing intelligent drug regimens tailored for a given 
patient. Therefore, many consortiums including ours have put efforts into deep 
profiling of serial samples from individual patients to design drug combinations 
targeting multiple cell populations in the hope of achieving a better outcome for 
the patient.  
 
In this thesis, we sought to expand our interpretation of clonal architecture of a 
tumor to include low-frequency subclones and developed methods to assess 
treatment response at subclone-level with acute myeloid leukemia (AML) as a 
model. We studied intra-tumoral heterogeneity (ITH) and its role in 
heterogeneous drug responses in AML and renal cancers. These studies provide 
methods to investigate cancer evolution and heterogeneity as well as understand 
drug responses at a subclone level. We believe, our personalized medicine-based 
approach to target cancer heterogeneity by designing smart drug combinations 
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targeting multiple sublones will probably reduce the evolutionary potential of a 
tumor by making it more homogenous and help reduce future relapses.  
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REVIEW OF THE LITERATURE 
1. BACKGROUND 
1.1 Mutational landscape of cancer 
Before we dive into exploring clonal evolution, it is pertinent to gain a 
comprehensive understanding of the mutational landscape of cancer and 
underlying processes that lead to accumulation of cancer mutations over time. 
Seminal paper by Vogelstein et al., reviewing the genomic landscapes of multiple 
cancers highlighted the diversity in mutational load of different cancers, although 
majority of the driver alterations converged into 12 key signaling pathways.14 
Tumors of the colon and lung as well as melanomas were among the top highly 
mutated tumor types with > 200 nonsynonymous mutations per tumor whereas 
leukemia’s were among the least mutated with < 25 mutations per tumor. Large 
chromosomal alterations including deletions, translocations and inversions were 
found to be frequent in solid tumors such as colorectal and breast cancers. With 
such diverse genomic alterations underlying each tumor, it is important to 
differentiate and categorize mutations that confer survival advantage for a tumor 
i.e., driver versus passenger mutations.  
 
Several cancer biology studies over time have identified mutations in genes such 
as TP53, APC, KRAS and their importance in driving cancers. Recent pan-cancer 
tumor sequencing efforts by consortia’s such as The Cancer Genome Atlas 
(TCGA) have provided a comprehensive list of recurrent gene aberrations in >30 
major cancer types, laying the groundwork for future cancer genomic 
investigations. Genes recurrently mutated in tumors indicate high likelihood of 
being crucial in driving the tumor. Although, for a mutation to be considered as 
a driving event, additional features such as functional significance of a mutation, 
whether it is in conserved regions, phosphorylation status, the variant allele 
frequency and the presence of multiple other mutations in the same gene need to 
be taken into consideration.15 Recent studies have published methods to identify 
such driving alterations from publicly available consortium data, thereby 
providing a comprehensive catalogue of driver genes in major cancers.15-23   
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1.1.1 Genomic alterations in AML 
AML is a heterogeneous disease characterized by evolving genomic landscape 
and acquisition of new mutations. Recent studies emerging from massive 
sequencing efforts have revealed comprehensive list of mutations driving AML 
from preleukemic phase to late relapse.24-26 In AML, the most common recurrent 
mutations occur in FLT3, NPM1, DNMT3A, NRAS, TET2, IDH1/2 and RUNX1 
driver genes. Chromosome level alterations such as chromosome 7/7q(del), 
8/8q(gain), 5/5q(del) are highly recurrent.24 Based on World Health Organization 
(WHO) classification, molecular subgroups of AML were defined based on 
specific set of chromosomal alterations and translocations.27 Re-evaluation of 
AML classification into subgroups based on cytogenetic analysis and sequencing 
of 111 key genes from 1540 AML patient samples identified 11 distinct classes 
of AML as shown in Figure 1. NPM1-mutated patients, with additional mutations 
in DNMT3A, FLT3, NRAS, PTPN11 and TET2 made up the largest cohort (27%). 
Interestingly, mutations in genes regulating RNA splicing (SRSF2, SF3B1, 
ZRSR2, U2AF1) and chromatin regulation mechanism (ASXL1, STAG2, EZH2, 
PHF6), which were previously not classified based on WHO, made up the second 
largest cohort (18%).24 Recent studies have highlighted the incidence of age-
related clonal hematopoiesis in non-AML healthy adults. Mutations in DNMT3A, 
TET2 and ASXL1 genes were found to be frequent (9-18%) in healthy individuals 
with >70yrs of age. These mutations are associated with increased risk of 




Figure 1: Genomic classification of AML into 11 major subgroups based on cytogenetic 
and sequencing analysis of 1540 AML patient samples. NPM1 mutation with co-
occurring alterations in DNMT3A, TET2, FLT3, NRAS and PTPN11 is the most recurrent 
followed by alterations in RNA splicing and chromatic regulating genes (RUNX1, MLL, 
SRSF2, DNMT3A, ASXL1, STAG2, etc). 
Reproduced with permission from “Genomic Classification and Prognosis in Acute 
Myeloid Leukemia” Papaemmanuil et al.24 Copyright Massachusetts Medical Society 
2016. 
1.1.2 Genomic alterations in RCC 
Clear cell renal cell carcinoma (ccRCC), the common type of cancer accounting 
to > 90% of kidney cancers, is often characterized by significant genomic 
heterogeneity at both inter and intra-tumoral level. 31 Large-scale sequencing 
efforts have identified recurring somatic alterations in driver genes such as VHL, 
histone modification and chromatin remodeling genes (PBRM1, SETD2, 
KDM5C) and genes belonging to PI(3)K/AKT/MTOR pathway.32-35 VHL 
NPM1 (co-occuring with  DNMT3A, 




TP53, aneuploidy, or 
both

















With driver mutations 
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mutations are highly recurrent in ccRCCs and seen in up to 90% of ccRCC cases. 
Its inactivation leads to degradation of hypoxia inducible factor (HIFα) 
transcription factor family leading to a range of downstream effects in pathways 
involved in angiogenesis, glycolysis and anabolic biosynthesis.36-39 Recurrent 
mutations in PI(3)K/AKT/MTOR pathway have a critical impact on cell growth 
and proliferation leading to tumor progression.40 Therefore, MTOR inhibitors are 
highly interesting therapeutic agents for inhibiting PI(3)K/AKT pathway.41,42 
Although, underlying intra-tumoral heterogeneity between distinct tumor regions 




2. CANCER EVOLUTION AND HETEROGENEITY 
2.1 A brief history 
‘Nothing in biology makes sense except in the light of evolution’  
Theodosius Dobzhansky 
 
Peter Nowell introduced the concept of cancer as an evolutionary phenomenon 
similar to the process of Darwinian evolution in 1976, nearly four decades ago.45 
But, not until recently has the concept of competing evolution among cancer 
clones been revisited.43,46-51 Pivotal studies on clonal architecture and evolution 
of somatic mutations in acute lymphoid and myeloid leukemia beautifully 
described the origin and evolution of subclones from diagnosis to later relapses, 
while capturing the impact of therapy on reshaping the tumor 
subpopulation.46,49,52 So what enabled us to re-establish cancer as an evolutionary 
mechanism which was first proposed over four decades ago? 
 
The first human genome sequence was published after a decade of massive 
collaborative effort in 2001.53 Since then, the price of sequencing has 
dramatically fallen, even exceeding the Moores law.54 Reduction in sequencing 
costs led to a barrage of cancer genome sequencing efforts resulting in detailed 
evaluation and cataloguing of cancer genome and associated mutations. The 
coordinated acquisition of cancer genome data led to the identification of novel 
cancer driver events, reclassifying tumors based on their molecular profile, 
improved diagnostics and development of new targeted therapies. Another key 
concept of cancer that gained significant leverage with advancement of next-
generation high throughput sequencing was the existence of genetic 
heterogeneity in tumors. Many recent studies on genome sequencing of tumors 
from multiple time points during the course of disease progression provide 
evidence of clonal evolution and selective pressure of therapy on cancer 
subclones in an unprecedented detail. Evolution of cancer, a concept introduced 
four decades ago, has now been demonstrated effectively with the advent of next-




2.2 Evolution in cancer 
The Darwinian theory of evolution by natural selection55 is based on the 
following three basic principles: 
1. Diverse group of organisms evolve from common shared ancestors 
2. Phenotypic variations that are heritable are acquired in each generation 
3. These variations confer natural selection, wherein positive traits are 
selected for the next generation resulting in “survival of the fittest” 
 
This Darwinian model system of evolution is reminiscent of how cancers evolve 
overtime. A cancer cell is basically a normal cell gone rouge with unchecked 
proliferation and invasive capacity while accumulating mutations that confer 
survival advantage over normal cells. Cancer cells evade checkpoints such as 
programmed cell death, apoptosis and immune surveillance resulting in 
accumulation of abnormal cells leading to tumor formations. Additionally, 
tumors are able to recruit normal cells and hack the cellular functions of the body 
to build a sustainable tumor microenvironment that supports the growth of the 
tumor and protects it from adverse effects such as therapy.56-59 Such a complex 
system of disease, evolves over time and is constrained by a range of selective 
pressures such as therapy, environmental effects and microenvironment as shown 





Figure 2: Factors influencing evolution of cancer cells from initiation to progression. 
Factors such as therapy and environment influence a cancer cell state resulting in 
genomic and epigenomic changes that lead to cancer initiation, progression and 
evolution over time.   
Adapted with permission from Springer Nature Publisher: Nature Medicine, “Toward 
understanding and exploiting tumor heterogeneity” Alizadeh et al.60 Copyright 2015
  
2.2.1 Clonal origin of cancer 
Cancer usually originates at cellular level, wherein a progenitor or normal cell 
stochastically accumulates heritable alterations that undergo selective pressure 
resulting in ‘survival of the fittest clones’. Every cell in human acquires 
mutations at a constant rate while aging, but these are usually “passenger” 
variations that do not result in extensive disruption of the cellular functions. 

















as oncogenes, tumor suppressors or DNA repair genes, this could lead to 
initiation of tumorigenesis. The number of driver alterations required to give rise 
to a malignant cancer cell varies between different cancers. Successive mutations 
acquired by the tumor initiating cells confer selective advantage to the cells 
leading to tumor progression. The availability of large-scale cancer genomic data 
has enabled the cataloguing of driver alterations in various cancers.15,18,63 The 
driving alterations could be predominantly point mutations or translocations in 
cancers such as AML, or copy number and structural alterations such as in 
prostate and ovarian cancers.25,52,64-66   
 
 
Figure 3: Clonal evolutionary model of cancer. Cancer clones arising from a common 
ancestor acquire additional mutations and branch out to subclones. Some of these 
subclones gain metastatic potential and seed tumor in a distant metastatic site. A 
snapshot of the primary and metastatic tumor shows heterogeneous population of cancer 
cells to include both early ancestral cell clones and subclones arising during the evolution 
of cancer. Adapted with permission from Springer Nature Publisher: Nature, “Clonal 
evolution in cancer” Mel Greaves, Carlo C. Maley,67 copyright 2012. 
 
Tumor initiating events happen at the cancer stem cell stage as seen in AML and 
CML wherein pre-leukemic mutations are acquired overtime by hematopoietic 
stem progenitor cells (HSPC).68 Cooperating mutations accumulated in HPSCs 
form a founder clone present in all tumor cells. Subsequently, the tumor 
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different cancer subclones (Figure 3).52,60,67-69 Selective pressures induced by 
factors such as therapy and chromosomal instability further shape the clonal 
evolutionary process. As a consequence of evolution, heterogeneous cancer 
subclones are formed resulting in intra-tumor heterogeneity. ITH in turn results 
in competition between multiple subclones leading to competing evolution 
thereby resulting in a circular problem of evolution leading to ITH and vice versa.    
2.2.2 Clonal evolutionary trajectories 
Cancers can evolve in a linear fashion, wherein mutations are acquired 
sequentially by the major clone resulting in subclones that can be traced back to 
the ancestral cancer clone. Alternatively, in branched evolution, different 
mutations are acquired by cancer cells resulting in diversification of the tumor 
into multiple subclones (Figure 4). Studies on clonal evolutionary trajectories 
have identified both linear (as shown in acute lymphoid leukemia46) and branched 
trajectories from a recent common ancestor (as shown in primary breast 
cancers70). These studies have shown how therapy can impact cancer evolution 
by creating evolutionary bottlenecks. Therefore, to understand the overall life-
history of a cancer and how external and internal factors such as therapy impact 
the evolutionary structure we must obtain and analyze longitudinal samples 




Figure 4: Clonal evolutionary trajectories of AML from early progenitor cells to later 
relapses.  A) Linear evolution of cancer: A single subclone is dominant at diagnosis and 
relapse and, B) Branched evolutionary model: Multiple subclones arising from early 
progenitor cells undergo selective pressures induced by factors such as therapy. As a 
consequence of therapy, subclones dominant at diagnosis are lost at relapse (red) or rare 
subclones at diagnosis emerge as therapy resistant subclones dominating at relapse 
(yellow) or remain at the same frequency from diagnosis to relapse (blue). 
Illustration by Christian Benner. Adapted by permission from Springer Nature Publisher: 
Nature, “Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-




Temporal and spatial collection of tumor samples enables in-depth query into the 
dynamics of clonal evolution during disease progression. Studies on intra-
tumoral heterogeneity of cancers between spatially distant primary and metastatic 
tumors have revealed branched evolution of the tumors, for example in renal cell 
carcinomas44, prostate cancers71, breast carcinomas70,72 and lung cancers73. Ding 
et al, comprehensively illustrated clonal evolution of AML patients from 
diagnosis to later relapse based on whole-genome sequencing of serially acquired 
tumor samples.48 The study showed how therapy could select for a previously 
existing low-frequency subclone to dominate the cancer cell fraction at relapse. 
Preleukemic stem cells in leukemia have shown to contribute to both resistance 
and relapse of cancers.26,74,75 Similarly, low-frequency subclones pre-existing at 
diagnosis have been shown to re-emerge and seed metastasis in a distant tissue 
in prostate cancer.71 The emerging picture of tumor complexity due to subclonal 
evolution and heterogeneity can explain the failure of chemo and targeted drugs 
to truly eradicate cancer which so far has not taken subclonal heterogeneity and 
evolution into consideration.  
 
Recent studies have proposed additional models of tumor evolution such as 
punctuated evolution, wherein large genomic aberrations accumulate in a short 
span of time either at chromosome or whole-genome level.76-79 This model of 
evolution has been referred to as the ‘big bang’ model leading to an evolutionary 
leap.80 Phenomenon’s such as chromothripsis, kataegis, chromoplexy, which 
cause large-scale genomic instabilities, can result in such a model of 
evolution.77,79,81,82 These are known to arise in multiple cancer types, but are not 
often seen in leukemias. 
2.3 Intra-tumor heterogeneity of cancers 
Branched evolution underlying intra-tumor heterogeneity between primary and 
metastatic sites in renal cell carcinomas revealed the extent of ITH in cancers.44 
ITH in cancer is not a new discovery; morphological heterogeneity of cancer was 
recorded as early as 1800s.83,84 Although the concept of ITH evolved with 
growing understanding of cancer biology such as discovery of genes, drivers and 
histopathological advancement, not until the recent advances in high-throughput 




Sequencing-based interrogation of ITH revealed branched evolution of cancer 
subclones wherein both ubiquitous mutations and site-specific mutations were 
identified.44,46,51,72,89 Metastatic sites in solid tumors are genetically distinct from 
the primary tumor tissue with subclones emerging specifically in metastasis. 
Phylogenetic analysis of ITH has revealed that in majority of cancers trunk 
mutations with most recent common ancestors are shared among spatially distinct 
sites.44,70,90 The cancer evolves by further branching out and as a consequence of 
evolution, mixed cell populations are generated leading to ITH. Despite the 
extent of ITH in cancers, recent studies are providing evidence of convergent 
evolution in tumors wherein, spatially and temporally distinct subclonal 
mutations converge to the same gene or pathway eventually.78,91 Evidence of 
convergent evolution has been seen in many cancer types where multiple 
mutations are found in a single gene or in genes belonging to the same pathway. 
46,78,92 Targeting these pathways could provide a strategy for exploiting ITH for 




3. CLINICAL IMPACT OF TUMOR EVOLUTION AND 
HETEROGENEITY 
Clonal evolution and heterogeneity has a profound impact on every aspect of 
clinical management of cancer such as diagnosis, treatment, disease 
management, trial designs, clinical follow up and drug discovery. Although, 
many recent studies have thrown light on the clonal complexity and heterogeneity 
of tumors, there has been minimal progress in constructing effective clinical trials 
and drug discovery processes to address the issue. Understanding the impact of 
therapy at a subclone level and interdependencies between multiple subclones 
will help us design strategies to tackle evolution and heterogeneity for the 
treatment of cancer.  
3.1 Impact of therapy on clonal evolution  
Chemotherapy is the first-line treatment strategy in hematological cancers.93 
Some of the chemotherapeutic agents act by disrupting cell division, inhibiting 
function of microtubules, interfere with DNA replication (antimetabolites) and 
inhibit topoisomerase enzymes. The indiscriminate and often genotoxic nature of 
chemotherapy results in a multitude of side effects including genomic instability, 
killing of the normal cell components including immune system, and could 
therefore contribute to the accelerated evolution of cancer.  
 
Studies in relapsed AML showed how chemotherapy not just failed to eradicate 
the founding clone, but led to the selection of chemotherapy resistant subclones 
that dominated at relapse.48 An increase in the number of transversions at 
genome-wide level was observed as a consequence of therapy as well. The ability 
of chemotherapy to induce random mutagenesis leads to heterogeneous cancer 
cell populations resistant to chemotherapy.94 Similar effects of chemotherapy on 
clonal selection and expansion have been reported in myelomas,95,96 
lymphomas,97 gliomas98-100 and lung cancers.101 Targeted therapies have also 
been shown to select for therapy-resistant subclones .102-104 Targeting a single 
vulnerability has usually resulted in incomplete eradication of subclones and re-
emergence of cancers resistant to the therapies used. Current targeted therapies 
in most solid and liquid cancers are usually targeting known recurrent 
“actionable” alterations without taking heterogeneity into consideration. Thus, 
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presences of tumor heterogeneity and cells intrinsically resistant to the drugs 
often leads to short-term remissions at best. 
3.2 Emergence of drug resistant clones  
Based on current knowledge, therapy can result in emergence of drug resistant 
subclones in the following ways: i) selection of a pre-existing drug-resistant 
subclone; ii) random mutagenesis leading to formation of novel drug resistant 
clone, iii) differential sensitivity of subclones leading to incomplete eradication 
of cancer cells or; iv) incomplete eradication of cancer stem cells.  Numerous 
studies have observed the pattern of selection for resistant subclones by 
therapy.98-100,102-105 A classic example of this case is imatinib, a small molecule 
tyrosine kinase inhibitor of BCR-ABL achieved tremendous success in treating 
chronic myeloid leukemia (CML). Although initially responsive, many 
advanced-stage CML patients relapsed by acquiring resistant mutations in BCR-
ABL rendering treatment with imanitib ineffective.103,104 Differential sensitivity 
of subclones to therapy resulting in emergence or outgrowth of new subclones 
have been reported by Landau et al and in our studies (paper I) Ojamies et al.106,107    
3.2.1 Clonal and subclonal mutations 
For the better understanding and targeting of drug resistant subclones, it is 
pertinent to classify clonal and subclonal mutations in the context of evolution. 
Mutations arising from early ancestral cell and present in all cancer cells are 
considered to be clonal or trunk mutations (Cancer cell fraction = 1). Whereas 
mutations present in a fraction of tumor cells are considered to be subclonal.60 
Targeting of trunk mutations alone, that is clonal mutations present in majority 
of the cancer cells, will result in emergence of low-frequency minor subclones at 
relapse or metastasis not targeted by the therapy. Also, for targeted therapy we 
need to consider if the targeted genes are clonal or subclonal. If the targeted genes 
form a minor fraction of cancer cells, this would result in ineffective therapy 
response. Landau et al. observed shorter event-free survival rate after therapy in 
patients with subclonal mutations when compared to patients without subclonal 
mutations. Therefore, subclonal mutations are an independent risk factor of 
relapse and disease progression.106 Given that pre-existing low-frequency 
subclones are seen to emerge at relapse, it is important to gain a comprehensive 
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understanding of the clonal composition and design therapies targeting multiple 
subclones.  
4. LONGITUDINAL AND SPATIAL SAMPLING OF 
TUMORS 
The dynamic nature of cancer evolution, therapy resistance and intra-tumor 
heterogeneity emphasizes the importance of sampling tumors during the course 
of the disease from multiple sites. Tumor sampling from a single site 
underestimates the extent of intra-tumor heterogeneity in tumors. Samples are 
typically taken in the clinic at diagnosis and infrequently during the course of the 
disease. Single time point sampling provides only a snapshot of alterations that 
have continually undergone evolutionary selection. Further, impact of therapy on 
the clonal heterogeneity and evolution of cancer is not captured from single time 
point samples limiting our understanding of drug resistance and therapy response.  
 
Therefore, an enhanced sampling strategy to include both longitudinal and 
spatially acquired samples from primary and metastatic tumors needs to be 
adopted. Although this approach is not clinically feasible, adoption of strategies 
such as sampling circulating tumor cells or DNA multiple times before, after and 
during therapy can shed light on emerging subclones, resistant mechanisms and 
mitigate the impact of ITH. Many recent studies have shown the validity of this 
approach in studying ITH and therapy response.108-111 
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AIMS OF THE STUDY 
The overall aim of the thesis was to comprehensively analyze clonal evolution 
and heterogeneity of cancer subclones and to delineate the impact of therapy at 
subclone-level in the context of individualized cancer treatment. For these 
studies, acute myeloid leukemia (AML) and renal cell carcinoma (RCC) –derived 
in vivo patient samples and patient cells in ex vivo culture, were analyzed. . 
 
The specific aims were: 
 
1. Develop improved methods to determine the clonal evolution of cancer 
during chemo- and targeted therapies, with a focus on low-frequency 
subclones in patients receiving treatment for AML.  
2. Investigate genetic heterogeneity between different bone marrow 
compartments in AML. 
3. Apply patient-derived cell cultures (PDCs) to investigate the evolutionary 




MATERIALS AND METHODS  
Material and methods used in this thesis are described in detail in the original 
publications (I-III). Below is the summary of materials and methods in brief. 
1. PATIENT STUDY MATERIAL – AML (I, II) 
For studies I and II, bone marrow aspirates (BM), peripheral blood (PB) and 
skin samples (germline control for sequencing experiments) were obtained from 
AML patients. Prior informed patient consent (Permit numbers 239/13/ 
03/00/2010, 303/13/03/01/2011) in accordance with the Declaration of Helsinki 
was received from Helsinki University Hospital Ethics Committee.  
For Study I, a total of 39 longitudinal BM samples from 12 AML and one high-
risk myelodysplastic syndrome (MDS) patient were collected. For Study II, 
mononuclear cell fractions of BM samples of two AML patients were obtained 
from three distinct sites each:  corpus sternum (CS), right and left iliac crest 
(RIC and LIC). Blast counts from bone marrow aspirates are detailed in 
respective publications. Mononuclear cell fraction was isolated from patient 
bone marrow and blood samples using density based gradient separation 
(Ficoll-Paque Premium; GE Healthcare, Little Chalfont, UK). Genomic DNA 
from the mononuclear cells and skin sample were isolated using DNeasy Blood 
and Tissue kit (Qiagen, Hilden, Germany). 
2. STUDY MATERIAL – RCC (III) 
2.1 Patient samples 
Tumor and benign tissue samples of four renal cell cancer patients were 
obtained from primary and metastatic sites. Histopathological characterization 
of benign and malignant cells was performed using hematoxylin and eosin 
staining. Signed informed consent (Dnro 263/13/03/02/2011; 
379/13/03/02/2012 and Dnro § 212, approved by Urological Biobank Initiative 
with Helsinki Urological Biobank; HUB) was obtained from patients in 
accordance with the Declaration of Helsinki. 
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2.2 Patient derived cultures (PDCs) 
Patient derived cultures from primary cells were established from conditionally 
reprogrammed cells (CRC). Hematoxylin and eosin staining was used to evaluate 
the ratio of benign and malignant cells from parental tissues to characterize tumor 
and benign tissue cells. Detailed description on method to establish the PDCs are 
described in the original publication III.  
3. GENOME SEQUENCING TECHNOLOGIES 
3.1 Whole exome sequencing analysis (I – III) 
Genomic DNA extracted from tumor, skin (I, II) and benign tissue (III) cells were 
used for whole-exome sequencing (WES) analysis. Initial exome capture on 3µg 
of DNA was performed using Agilent SureSelect Human All Exon V5 (Agilent, 
Santa Clara, CA, USA) or Nimblegen SeqCap EZ v2 capture kit (Roche 
NimbleGen, Madison, WI, USA) and sequencing was performed using Illumina 
Genome Analyzer IIx, HiSeq1500 or 2500 instruments (Illumina Inc., San Diego, 
CA, USA). On average we achieved 30x coverage for normal control and 100x 
coverage for tumor samples. Somatic mutations, i.e. tumor-specific variants and 
variant allele frequencies (VAF) were determined using VarScan2 algorithm112 
with the following parameters:  
 
- Strand-filter 1 
- Min-coverage-normal 8 
- Min-coverage-tumor 1 
- Somatic-P value 0.01 
- Normal-purity 0.95 
- Min-var-freq 0 
 
Mutations were annotated with SnpEFF113 using Ensemble v68 version. Cancer 
cell fraction was calculated to estimate tumor purity (in I) as described by Rubio-
Perez et al.114 The VAF were corrected for the cancer cell fraction. By doing so 





Copy number variations (CNV) were determined using in-house CNV analysis 
pipeline. Briefly, we calculated RPKM (reads per kilobase of target region length 
per million mapped reads) value for each target region from both tumor and skin 
control samples. Target regions with <25x coverage were excluded from analysis 
and relative log2 ratio of copy number calls for the tumor versus skin were 
calculated and segmented using Circular Binary Segmentation.115 Copy number 
changes were set at -0.4 (heterozygous deletion), -1.2 (homozygous deletion), 
+0.5 (gain) and +1.3 (amplification). 
3.2 Ultra-deep amplicon sequencing (I – II) 
Putative, clonal and subclonal driver mutations identified from WES data were 
validated using ultra-deep amplicon resequencing. Also, variants that were 
identified specifically at certain time points (diagnosis, relapse) were validated 
in all serial patient samples to determine if the variants were present at low-
frequency (Figure 5A).  
 
We performed amplicon resequencing using Illumina MiSeq instrument with 
MiSeq Control Software v2.4 or newer (Illumina, Inc., San Diego, CA, USA). 
Initially target sequence primers were prepared using in-house targeted PCR 
amplification protocols. The protocol used either one or two rounds of PCR 
amplification. In the two-step protocol, first amplification round was performed 
using 10-20 ng of sample DNA, 10 µl of 2x Phusion High-Fidelity PCR Master 
Mix (Thermo Scientific Inc., Waltham, MA, USA), 0,5 µM of each locus specific 
primer carrying Illumina-compatible adapter sequences at annealing temperature 
60 °C. Subsequently, samples were purified using Performa® V3 96-Well Short 
Plate (EdgeBio, Gaithersburg, MD, USA) and QuickStep™2 SOPE™ Resin 
(EdgeBio, Gaithersburg, MD, USA) according to the manufacturer’s 
instructions. A second round of PCR amplification was performed to include 
index primers carrying Illumina grafting P5/P7 sequence.  
 
Subsequent to PCR amplification, additional purification steps were performed 
with Agencourt® AMPure® XP (Beckman Coulter, Brea, CA, USA) according to 
the manufacturer’s instructions. We quantified amplification performance and 
amplicon yield on Agilent 2100 Bioanalyzer using Agilent High Sensitivity DNA 
Kit (Agilent Technologies Inc., Santa Clara, CA, USA). Samples were sequenced 
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as 251 bp paired-end reads and two 8 bp index reads on MiSeq sequencing 
platform. Further analysis on sequenced data was performed using an in-house 
amplicon analysis pipeline.  
 
 
Figure 5: UMI-based ultra-deep amplicon sequencing approach. A) We estimated clonal 
composition, driver mutations and diagnosis or relapse-specific mutations from serial 
samples acquired during the disease course. Mutations belonging to either of the three 
criteria were selected for further validation using ultra-deep amplicon resequencing. B) 
To enhance rare variant calling, we generated 16384 UMIs and tagged DNA fragments. 
Subsequent to PCR amplification and sequencing, reads with expected UMI 
combinations were selected for and further base quality filtering was performed. 
Variants were called from the resulting filtered data.  
 
3.2.1 Unique molecular identifier (UMI) based ultra-deep 
amplicon sequencing (I, II) 
We utilized UMI-based ultra-deep sequencing approach to enhance variant 
calling by reducing mismatch errors introduced by PCR amplifications, 
sequencing errors, low quality sequences, among others. We adopted a non-
random approach for generating UMIs wherein 128 degenerate 6 bp sequences 
with an edit distance of 2 bp and non-complementary to the index sequences are 
Tag DNA fragments with UMIs




Read bins with expected UMI combinations
Filter bases with Phred
quality < 20
Filter variants with
strand bias > 80%
Call true variants













generated. This approach has two advantages. Firstly, by utilizing combination 
of non-random UMI’s (128x128 degenerate sequences), we were able to have 
control over sequencing errors in the barcode regions and have prior knowledge 
of the expected UMI combinations.  Secondly, in our case with low sample 
amounts, UMI’s enabled efficient multiplexing and increased sensitivity of low 
variant calls in a cost-effective manner. In order to remove contaminating 
germline variants, we performed amplicon sequencing on matched skin control 
and normal DNA control samples. Rigorous data filtering steps were 
implemented to reduce mismatch and PCR introduced errors and enhance true 
variant calling (Figure 5B). 
4. DRUG SENSITIVITY AND RESISTANCE TESTING 
(DSRT) (I, III) 
We performed ex vivo DSRT on patient-derived bone marrow mononuclear cells 
(in Study I) and patient-derived cell cultures (PDC’s in Study II) with 306 
clinically approved and emerging oncology drugs as described by Pemovska et 
al116. Cells were incubated in five different drug concentrations for 72 h. 
Subsequently cell viability was determined with CellTiter-Glo (CTG, Promega, 
Madison, WI, USA). Dose response curves were generated for each drug using 
Dotmatics Studies software (Dotmatics Ltd., Herts, UK). We quantified drug 
response of each drug in a sample by estimating drug sensitivity score (DSS). 
The DSS score was estimated as described by Yadav et al.117   
5. STATISTICAL ANALYSIS (I-III) 
Statistical analyses were performed with R statistical software (http://www.r-
project.org/) and Prism software version 6.0 (GraphPad Software, San Diego, 
CA, USA). Correlation analysis between two variables was assessed using 
Pearson’s correlation (two-tailed) or Spearman’s rank correlation analysis. 
Linear regression method was applied to fit longitudinal data points collected 
during disease progression.  
5.1 Correlation matrices (I, II) 
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For spatially and temporally acquired tumor samples, we developed a correlation-
based method to visualize the subclonal composition of the patient. Briefly, based 
on correlation scores of VAF’s across multiple time points, we quantitatively 
modelled clonal composition. Using trend estimation based on linear regression 
models, we tracked subclonal response to therapy. Based on these two estimates, 
we were able to delineate mutations from longitudinal samples into specific 
subclones. Significance of subclonal response to therapy was determined based 
on χ2 test of absolute variant reads of sample taken before and after treatment. A 
positive correlation between mutations indicates that they are part of the same 
sublcone, whereas a low or negative correlation score indicates the probability of 
the two mutations forming part of distinct subclones.  
6. PHYLOGENETIC ANALYSIS (II, III) 
We reconstructed cancer phylogeny to understand the clonal relation and 
progression among multiple tumor samples using the method published by Popic 
et al.118 Briefly, the method robustly groups the samples based on the presence 
or absence of mutations in a subgroups. These groups are further clustered using 
expectation-maximization clustering algorithm for Gaussian mixture models. 
Phylogenetic trees are constructed based on maximum parsimony method. We 
implemented the tool to study cancer evolution from anatomically distinct bone 
marrow compartments in Study II and between primary, metastatic tumors and 
respective PDC’s in Study III. The following parameters were used for the 
analysis:  
 
-maxVAFAbsent 0  
-minVAFPresent 0.0001  
-minClusterSize 4  






1. MONITORING THERAPY RESPONSE AT SUBCLONE-
LEVEL  
1.1 Personalized medicine platform for analyzing subclonal 
therapy response 
As part of our individualized systems medicine (ISM) program, therapies are 
tailored for chemorefractory AML patients based on integrated information from 
genomic profiling and functional drug response and resistance profiling (Figure 
6). 
 
In Study I, we analyzed longitudinal samples taken at diagnosis, relapses, before 
and after therapy from 13 chemorefractory AML patients. Six of the 13 patients 
received targeted therapies based on the results from the ISM approach. This 
enabled us to monitor subclonal responses to both chemotherapy (13 patients) 
and to targeted therapy (six patients). Initially, we performed WES to identify 
somatic variants and determine clonal composition of each patient sample. 
Subsequently we performed ultra-deep amplicon resequencing with UMIs to 
validate subclonal mutations as well as to identify rare variants not detected by 




Figure 6: Overview of clonal evolution and response to therapy approach as part of the 
individualized systems medicine (ISM) program. Serial tumor samples obtained at 
diagnosis and during disease progression were subjected to DSRT, exome-sequencing 
and ultra-deep amplicon sequencing analysis. Based on the obtained data, we interpreted 
clonal evolution, heterogeneity and therapy response of individual subclones that 
enabled us to design combinatorial therapy regimens to target multiple subclones. The 
information gained is translated to the clinic, thereby providing an effective feedback 
loop between research and clinical translation.  
1.2 Methodologies for interpreting subclonal architecture and 
therapy response from multiple time point samples 
In this study, we developed improved methodologies to: i) enhance the detection 
of rare subclonal variants (frequency < 10%), ii) comprehensively estimate 
subclonal composition from serially acquired samples and iii) assess the impact 
of therapy on individual subclones over multiple time points.  
 
To enhance detection of low frequency variants, usually undetected by whole 
exome or genome sequencing efforts due to low signal-to-noise ratio we 
developed an ultra-deep amplicon resequencing with UMI based approach. The 
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method enabled sensitive detection of low-frequency variants by achieving very 
high coverage (>10000x). By utilizing UMIs in addition to relevant filtering steps 
we were able to significantly minimize the noise, while enhancing the sensitivity 
to detect low-frequency variants. Using this approach, 16 low frequency variants 
(0.5% - 2%) could be identified, that were undetected by WES. In one such case, 
we identified PHF6 variant in patient #706 present at low frequency. The variant 
was seen at 20% frequency at relapse but was not detected at diagnosis. We could 
validate the variant to be present at 0.5% frequency at diagnosis, by significantly 
reducing the background noise at such low frequency levels (Figure 7). 
 
 
Figure 7: Before (A) and after (B) implementation of UMI-based filtering approach to 
optimize variant calling of low-frequency PHF6 variant. A significant reduction in the 
background noise level is shown after implementing the filtering while validating the 
authenticity of the PHF6 variant to be true. Inset in B shows the PHF6 variant in detail.  
 
Secondly, to estimate subclonal composition from temporally acquired tumor 
samples, we implemented a correlation-based method wherein we built 
correlation matrices (Pearson correlation) for each variant based on their allele 
frequencies in different time points. The likelihood of each variant belonging to 
a subclone was determined based on the correlation coefficients. A positive 
correlation between mutations indicates that they are likely to form part of the 
same subclone, whereas a low or negative correlation score indicates the 
probability of the mutations forming part of distinct subclones. Using this 
approach, we quantitatively modelled clonal composition. For example, in 
patient #1145 we identified here distinct subclones based on their correlation 
scores (Figure 8A). Mutations in JAK3, STED2, PHF6, NOTCH2 and RUNX1 









































































































































belong to the same subclones. However, these subclonal mutations had a negative 
correlation score with TP53, CBL and PTPN11 indicating that these mutations 
belong to a separate subclone (Figure 8A). 
 
To estimate the impact of subclones on therapy response, we performed trend 
analysis using linear regression models. With the availability of longitudinal 
samples before and after therapy, linear trend estimation helped us identify if 
mutations arising at later time points belonged to the same subclone or a different 
one. For example, in patient #1145, by comparing variant allele frequency of 
TP53 against other mutations, we saw a linear trend of subclonal variants 
segregate. Subclone with PTPN11 and CBL showed a positive slope whereas the 
other subclonal variants had a negative slope in correlation to TP53 (Figure 8B). 
Additionally, to determine the significance of subclonal response to therapy, we 
performed χ2 test of absolute variant reads of sample taken before and after 
treatment. 
 
Figure 8: A) Correlation matrix indicating subclonal composition of the leukemic cells 
in patient #1145. Genes with grey block highly correlated among each other whereas red 
blocks indicate negative correlations. We saw at least three distinct subclones based on 
these mutations. B) Linear trend analysis indicated the trend of all subclonal mutations 
in comparison to TP53 mutations. In this case, we saw that the subclones were each 
responding differentially in comparison to each other.  
1.3 Subclonal responses to chemotherapy 
We observed responses of individual subclones to chemotherapy in 13 AML 




















































compared untreated diagnostic samples against samples taken after therapy to 
study i) differential response and resistance of subclones to chemotherapy and ii) 
emergence and loss of subclonal mutations subsequent to therapy. Based on chi-
square trend test we found statistically significant response (p < 0.0001) of 
individual subclones to chemotherapy. Interestingly, we discerned either 
emergence or loss of subclonal mutations in response to therapy. In patient #600 
we observed emergence of new mutations as well as selection of existing 
mutations in WT1 gene after chemotherapy (Figure 9A).  The data obtained 
implies the selective pressure of chemotherapy on existing subclones and the rise 
of new, potentially cancer driving, mutations. In patient #706, we observed three 
different subclones responding in a completely different fashion (Figure 9B). A 
dominant subclone with driver mutations in DNMT3A and TET2_1 responded 
only marginally to therapy. Whereas, subclone with NPM1 and TET2_2 was 
almost completely eradicated after chemotherapy. Thirdly, we saw emergence of 
a novel subclone with PHF6 mutation at relapse, which was present as a minor 
subclone at diagnosis (0.5%). This case illustrates the differential effect therapy 
could have on subclones and how chemotherapy acts as a bottleneck leading to 























































VAF (%) Coverage VAF (%) Coverage
TET2_1 41 3868 24 24503
INPP4A 46 20963 27 19652
DLEC1 44 48904 27 59323
DNMT3A 46 646 31 7510
PHF6 0.5 15430 26 35355
TET2_2 42 10542 0.8 38638
NPM1 38 2686 0 2384
Gene
600_D 600_R1 600_R2 600_R3
VAF (%) VAF (%) Coverage VAF (%) Coverage VAF (%) Coverage
WT1_1 0.00 7.91 217053 7.27 196591 0.00 306339
WT1_3 2.40 19.54 189014 20.58 167260 5.74 288390
WT1_4 0.00 20.57 185750 19.97 168284 32.32 205135
H2AFZ 1.57 35.04 394953 36.69 391879 40.72 465380
SDR42E1 1.75 38.06 247275 37.87 254216 39.36 219577
WT1_2 3.20 39.32 140901 38.28 127786 37.03 192058





Figure 9: A) Subclonal dynamics of the leukemia cell population in patient #600 from 
diagnosis to relapse. We see new emerging subclonal mutations in WT1 at first relapse 
(600_R1). WT1-1 mutation responded to therapy and was eventually eradicated but 
WT1-3 and WT1-4 were resistant to therapy indicating that they belong to a different 
subclone and have acquired resistance to therapy.  B) In patient #706 we see differential 
response of subclones to chemotherapy; 1) a dominant clone that remained unaffected 
by therapy, 2) a diagnosis – specific subclone that responded to therapy and was not seen 
at relapse, and 3) a subclone with PHF6 mutations reemerging at relapse as a dominant 
clone from a pre-existing low-frequency subclone at diagnosis. 
1.4 Subclonal responses to targeted therapy 
Six of the 13 patients were given individually tailored targeted therapies based 
on the ISM approach. We aimed to delineate the response of targeted therapy on 
individual subclones from samples taken before and after therapy. Based on 
clonal variant frequencies in five of the six patients, we observed significant 
reduction in clonal frequencies indicating response to targeted therapy (p 
<0.0001).  
 
Patient #560 received temsirolimus-dasatinib targeted therapy based on drug 
response profiling data.  Objective clinical response based on the European 
LeukemiaNet (ELN) criteria119 was not observed for this patient. We acquired 
five serial samples from diagnosis to later relapse, including samples taken 
during, before and after the targeted therapy (Figure 10A). We identified a 
dominant subclone with GATA2DB and CBFB mutations at diagnosis (#560_D), 
which then acquired additional mutations of BRCA1, PTPN2, PTPN11 and 
MLH1 genes, detectable at relapse (#560_R1). An additional subclone with CBL 
mutation was seen at relapse (Figure 10B). Subsequent to given targeted 
temsirolimus-dasatinib therapy we observed a significant quantitative response 
to therapy for both subclones during therapy, with the average VAF decreasing 
to 4% (p: 0.003). The patient however relapsed quickly, reflected also by the 
increasing subclonal frequency (average VAF: 21%) of the sample taken at 
relapse (#560_R2). This indicates that the two subclones acquired resistance to 
therapy (Figure 10C). Although the patient showed no response by objective 
clinical evaluation based on ELN criteria, a transient quantitative response at the 





Figure 10: (A) The disease course and frequency of subclones in patient #560 at five 
different time points. Blast percentages are shown on top. Patient received chemotherapy 
and targeted temsirolimus-dasatinib -based therapy. In this patient, two subclones with 
mutations affecting CBL in one clone and BRCA, PTPN11, PTPN2 and MLHI in other, 
were gained at first relapse. We observed both subclones responding to therapy as 
indicated by decreased subclonal frequency at 560_T and subsequently the subclones 
acquired resistance to therapy and dominated at relapse (560_R2). (B) Schematic 
representation of evolution of AML in #560. Based on the VAF over multiple time points 
we can hypothesize that mutations affecting BRCA1, PTPN11, PTPN2 and MLH1 were 
acquired in the same cells with GATA2DB and CBFB mutations, resulting in a dominant 
















































































separate subclone and that at 560_R1 majority of the cells were seen carrying CBL 
mutation. (C) Plot depicts the VAF of subclonal variants in samples taken before therapy 
(560_R1), during therapy (560_T) and after therapy (560_R2). We see a significant 
decrease subsequent to therapy and an increase in frequency after therapy indicating 
emerging resistance (χ2 test, P = .003). 
 
For patient case 1886, serial samples from diagnosis and three subsequent 
relapses were analysed after chemotherapy and individually chosen targeted 
therapies (Figure 11A). Clonal analysis revealed a major clone with DNMT3A, 
FLT3 and NPM1 mutations. As illustrated, mutations in DNMT3A were followed 
by acquisition of FLT3 mutations (Figure 11B). Based on the VAFs we could 
determine DNMT3A-FLT3 mutated subclonal cells as well as non-mutated cells 
acquiring NPM1 mutation, resulting in two distinct subclones. Additionally, a 
minor subclone with STAT5A, MTOR and CBL mutations, not detected at 
diagnoses (despite of an average sequencing coverage >11000x), emerged at 
relapse. Since the patient received a bone marrow transplant, we cannot ascertain 
if the minor subclonal mutations were cancer-specific or donor-derived 
polymorphisms. KIAA1209-PDGFRB fusion gene was detected at diagnosis and 
relapse, but could not be followed up due to unavailability of RNA sample.  
 
Subsequent to first relapse (#1886_R1), the patient received azacitidine and 
sunitinib therapy based on the presence of PDGFRB fusion gene as wells as FLT3 
mutations which both link to sunitinib sensitivity.120-122 Furthermore, ex-vivo 
sensitivity verified the responsiveness to sunitinib. Subsequent to 
azacitidine/sunitinib treatment, the patient showed a complete clinical response 
and we observed a significant response at subclone level (p < 0.0001). Following 
this, the patient received targeted treatments with dasatinib and axitinib-
everolimus but did not exhibit a clinical response. Although, we observed 
significant response of the minor subclone with mutations affecting MTOR-CBL-






Figure 11: (A) The disease course and frequency of subclones in patient #1886 at five 
different time points. Patient initially received chemotherapy and subsequently 
individually tailored therapy based on ex vivo drug response profiles. Shown in the plot 
are responses of the different subclones to therapy over multiple time points. We 
observed that both chemo and targeted therapies did not have high impact on the 
DNMT3A, FLT3 and NPM1 – mutated subclone, resulting only in transient responses to 
targeted therapies tailored for the patient. (B) Schematic representation of evolution of 
AML in #1886. Mutation in DNMT3A represents an early pre-leukemic event, followed 
by mutations in FLT3 and NPM1 in the same clone. Due to the difference in VAF of 
mutated DNMT3A-FLT3 and mutated NPM1 over multiple time points, it is likely that a 
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2. GENETIC HETEROGENEITY BETWEEN SPATIALLY 
DISTINCT BONE MARROW SITES IN AML 
In Study II, we investigated if genetic heterogeneity exists between anatomically 
distant bone marrow compartments of AML patients. For this study, we acquired 
bone marrow aspirates from three bone marrow sites: corpus sternum (CS), right 
and left iliac crest (RIC and LIC). We performed WES followed by validation 
with ultra-deep amplicon resequencing to study the underlying heterogeneity of 
each sample. For this study, we recruited two AML patients. Patient case AML1, 
aged 74, was first diagnosed with MDS and later relapsed with secondary AML. 
The patient received azacitidine-based treatment, during which we obtained the 
BM samples. Patient case AML2, aged 72, received cytarabine-idarubicine -
based induction therapy subsequent to AML diagnosis. The patient relapsed after 
two years, at which point the BM samples were biopsied.   
 
In patient AML1, exome sequencing data of multiple bone marrow samples was 
used to identify 42 high confidence somatic mutations (somatic p value < 0.01). 
Of these, 18 mutations were shared between RIC and CS, but were not detected 
in LIC. Subclonal composition of the leukemic blasts, inferred based on 
correlation coefficient matrices, identified three distinct subclones in this patient. 
Further, we inferred cancer cell lineage of the multiple BM samples from the 
common ancestor using phylogenetic analysis tool LICHeE.118 The phylogenetic 
analysis revealed the genetic relation between the three BM compartments and 
underlying clonal heterogeneity. All three compartments shared a common 
ancestral clone with 10 mutations in genes such as C22ORF43, TRPV3 and 
ANO9. Subsequently, the BM sites evolved in parallel, wherein two different 
subclones arose from the ancestral cell (Figure 12). One of the subclones with 
seven mutations was shared among the three sites. The other subclone with 16 
mutations, including variants in known driver genes such as PHF6, CABS1 and 
ZRSR2, was acquired by cancer cells in RIC and CS only, resulting in the 
branching out of the two sites from LIC making them genetically distinct. 
Interestingly, the subclonal frequency varied significantly between the two sites 
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Figure 12:  Inferring genetic heterogeneity between multiple bone marrow 
compartments of patients AML1 and AML2. We estimated clonal composition of the 
two patients using correlation-based analysis. As shown in the correlations matrices, we 
identified three major subclones in AML1 and at least four major subclones in AML2. 
Subsequent phylogenetic analysis of the two patients revealed genetic interdependencies 
of the multiple bone marrow compartments. Numbers indicated in the circles refer to the 
number of subclonal variants whereas subclonal frequencies in percentages are indicated 
on the branches. In AML1 we observed LIC to be genetically distinct from RIC and CS. 
The subclonal frequencies were significantly different between RIC and CS. Similarly, 
in AML2 we observed CS to be genetically distinct from RIC and LIC. Also, subclonal 
frequencies varied significantly between RIC and LIC.  
 
In patient AML2, we identified 50 somatic mutations of which 40 were 
ubiquitous among all three sites, five mutations were shared between RIC and 
LIC and three mutations were shared between LIC and CS. We identified four 
distinct subclones in AML2 from correlation analysis (Figure 12). Cancer cell 
lineage inferred from phylogenetic analysis showed the first common ancestral 
clone with 16 mutations, including those affecting known driver genes RUNX1, 
SF3A1 and FILIP1. The ancestral clone eventually acquired additional 16 
mutations in all three sites. Subsequent to this, RIC and LIC specifically acquired 
four additional mutations including one in SF3A1, a known AML driver gene, 
resulting in genetic diversification from the CS site. Similar to AML1, we 
observed significant difference in subclonal frequency between the two sites 
(15% and 25% in RIC and LIC respectively).  
3. GENETIC HETEROGENEITY UNDERLYING DRUG 
RESPONSES IN RENAL CELL CARCINOMA 
In Study III we developed patient-derived cell cultures (PDCs) from benign, 
primary tumor and metastatic tumor tissues of four renal cell carcinoma patients. 
We performed exome sequencing of both the tissue of origin and PDCs for all 
patients and drug sensitivity and resistance testing for PDCs with 460 approved 
and investigational oncology drugs.  The aim of the study was to i) infer clonal 
heterogeneity and evolution of primary, metastatic tumors and their respective 
PDCs, ii) analyze how representative the PDCs are of their respective tumor 
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tissues from which they were derived, and iii) study the impact of genetic 
heterogeneity on drug response profiles. 
3.1 Genetic heterogeneity and relation between multiple tumor 
sites and established PDCs 
Somatic mutations inferred from WES data were compared between tumor 
tissues and their respective PDCs of renal cell carcinoma (RCC) patients. Of the 
four cases (RCC.1-4), we found three patient models to be highly representative 
of their parental tissues (RCC.1-3) based on shared somatic mutations and copy 
number alterations (CNAs). In RCC.1 we identified alterations in known driver 
genes such as VHL, PBRM1, KDM5C, TSC2 and PIK3C2 in the tumor tissue, 
which were recapitulated also in the PDCs. Similarly, RCC.2 and RCC.3 parental 
tissues and PDCs shared common recurrent alterations such as deletions of 
chromosome 14 (affecting genes xx), 3p (VHL, PBMR1, SETD2, BAP1) and 9p 
(CDKN2A/B) and amplification of 7p (EGFR). RCC.4 PDCs did not share 
mutations with the parental tissue and therefore was not representative of the 
tumor.  
 
To extend our understanding of the clonal relation between parental tissues and 
PDCs we performed phylogenetic reconstruction analysis to infer the cancer cell 
lineage among the different samples using LICHeE tool. In patient case RCC.1, 
consisting of four samples (tumor tissue, metastatic tissue and their respective 
PDCs), we observed a common ancestral cell clone with 36 mutations (Figure 
13A). Subsequently, four additional mutations were acquired by the tumor PDC, 
metastatic tissue and metastatic PDC. These subclonal mutations were not 
identified in the tumor tissue. The metastatic tissue acquired 10 additional 
mutations resulting in a subclone specific to metastatic tissue, which was not seen 
in any other sample.  
 
Similarly, for patient case RCC.3, with primary tumor tissue sample, two 
metastatic samples (vena cava and secondary metastasis) and their respective 
PDCs (six samples in total), we could reconstruct the phylogenetic tree based on 
the somatic mutations. In this case, a common ancestral clone with nine mutations 
was shared among all samples and was the only identified cancer clone in tumor 
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PDC. PDC derived from the vena cava site did not share any mutations and 
branched away from other samples. Subsequently, the ancestral clone acquired 
mutations sequentially resulting in emergence on new subclones and branching 
out of the tumor tissue, metastatic tissues and PDC as shown in Figure 13B. The 
order of mutation acquisition and subsequent branching of the samples reflects 
the clonal evolution and genetic drift observed in patient RCC.3. In this case the 
PDCs also reflect similar pattern of clonal evolution (except vena cava PDC), 
thereby indicating that the PDCs not just shared the subclonal mutations but 
could also recapitulate the clonal evolutionary processes.  
 
 
Figure 13:  Genetic and drug response heterogeneity profiles of RCC.1 (A) and RCC.3 
(B). Phylogenetic analysis of somatic variants from tumor, metastatic tissues and their 
respective PDCs revealed the cancer cell lineage in the patient cases from the germline 
cell (GL). Numbers indicated in the circle reflect the number of variants that form part 
of the subclone. The average VAF of the subclones are indicated on the branches. The 
square boxes represent the tumor sample with the composing subclones. Based on the 
drug response profiles of the PDCs, we identified drugs that were responding specifically 
in tumor or metastatic PDCs. Top differentially responding drugs are shown next to the 
corresponding PDC in the figure.   
3.2 Impact of genomic heterogeneity on drug response profiles 
In order to study the impact of genomic heterogeneity on drug responses, we 








































sensitivity and resistance data of individual PDCs from tumor and metastatic sites 
to >450 approved and investigational oncology drugs. We observed interesting 
correlations between site-specific mutations and response to targeted therapies. 
In patient case RCC.1, the ancestral clone carried mutations in VHL, PIK3C2A, 
PBRM1, KDM5C and copy number alterations in gene loci for EGFR and 
CDKN2A/B (Figure 13A). We observed significant response of mTOR/PI3K 
inhibitors such as omipalisib, pictilisib, AZD2014 in both primary and metastatic 
PDCs, indicating that the common shared mutations could underlie comparable 
but significant responses to mTOR/PI3K inhibitors, which are currently being 
investigated for treatment of RCC patients.123 We observed selective responses 
in the primary and metastatic PDCs which can be hypothesized to be the result 
of site-specific subclones that were identified based on the phylogenetic analysis. 
Importantly, we observed significantly high response to BET inhibitors JQ1 and 
OTX015 and VEGFR inhibitors gefitinib and erlotinib in primary tumor PDC, 
which showed no response in the metastatic PDC. Conversely, we found anti-
mitotic inhibitor ABT-751 and topoisomerase inhibitor topotecan (approved 
ovarian cancer drug124) to be highly sensitive in metastatic PDC but not primary 
tumor PDC. 
 
In patient case RCC.3 we observed significant response to mTOR/PI3K 
inhibitors (AZD2014, omipalisib and ZSRK474), BET inhibitors (JQ1, OTx015 
and I-BET151) and topoisomerase inhibitors (camptothecin, topotecan and SN-
38) across all three PDCs (Figure 13B). Presence of BRD4 mutations in the 
ancestral clone shared among the PDCs could explain the response to BET 
inhibitors.125-127 Distinct PDC-specific responses were observed in RCC.3 case 
as well.  Tumor and secondary metastatic PDCs which were genetically distant 
from vena cava metastatic PDC showed sensitivity to mTOR inhibitor 
temsirolimus, an approved drug for treating RCC.42,128 Interestingly, we noted 
VEGFR inhibitors tivozanib and regorafenib to be highly sensitive in vena cava 
metastatic PDC in comparison to the other two PDCs. Both these cases clearly 
illustrate the underlying intra-tumoral heterogeneity of not just genomic 





The work presented in this thesis were designed to build on the FIMM 
individualized systems medicine (ISM) platform by studying how cancer evolves 
in time and space, while taking into consideration the impact of therapy. We 
aimed to develop methods that would allow the monitoring of the impact of 
treatment choices made and retrospectively understanding the mechanisms 
behind drug responses and drug resistance in heterogeneous, evolving tumors. 
The methods developed as part of the thesis are applicable to any cancer type, 
wherein longitudinal or spatial samples are acquired in a personalized medicine 
setting. Further, I will expound on the major lessons learnt from the studies in 
this section.  
1. SUBCLONAL RESPONSES TO THERAPIES 
As part of our individualized medicine strategy, we developed and implemented 
novel analytical tools to track subclonal responses following chemotherapy and 
tailored patient treatments. 
 
In Study I, we tracked subclonal-responses to therapy in 13 AML patients from 
diagnosis to later relapse. Six patients received tailored treatments based on the 
ISM approach. In this study, we established methods to i) enhance rare variant 
calling by utilizing UMI-based ultra-deep resequencing approach, ii) quantify 
subclonal composition by implementing correlation and linear-trend analysis, 
and iii) track subclonal responses to therapy from diagnosis to relapse. Previous 
studies on clonal evolution with whole exome or genome sequencing at 100-
300X coverage provide sensitivity to reliably track only clones present at greater 
than 5-10% frequency.106,129 Detection of low-frequency subclones by genome-
wide sequencing is technically challenging and obviously not feasible at this 
depth.48,106,129 Ultra-deep amplicon resequencing therefore complements exome 
sequencing, providing a comprehensive picture of the clonal evolution in AML 
during disease progression by enabling detection of rare subclonal variants at 
specific sites of the genome. Using this approach, we achieved an average 
sequencing coverage of 68,500x, allowing the detection of subclones and 




From the 13 AML cases, we observed significant differential responses of 
leukemic subclones to both chemo and targeted therapies. Of the six patients who 
received tailored targeted therapies, we observed significant subclonal responses 
in five patients. For example, patient case #560 was categorized as a non-
responder with recurrent disease based on ELN criteria119 but we quantified 
significant response of all major subclones to temsirolimus-dasatinib therapy. 
Therefore, we believe that estimations of therapy responses utilizing subclone-
level data provides a more comprehensive, quantitative and biologically more 
relevant picture of the molecular impact of the treatment. Drug response data on 
cell subclones will provide valuable insights on the cause of resistance. Therefore 
subsequent therapies can be targeted to inhibit the potentially emerging resistant 
subclones when possible. Further, we detected new subclones arising specifically 
at relapse and expansion of rare subclones at relapse that were pre-existing at 
diagnosis. These minor subclones were present at very high frequency at relapse, 
indicating therapy-based selection leading to selection of drug-resistant 
subclones. Taken together, we believe that monitoring of subclonal responses to 
therapy, enabled by ultra-deep amplicon sequencing approaches, provides 
valuable insights on drug resistance and sensitivities which forms an important 
basis for future drug development and personalized medicine strategies. In this 
study, we retrospectively confirmed that relapse-specific subclonal variants 
existed already at diagnosis as low frequency subclones. Therefore, it is critical 
to develop approaches that can identify these variants prospectively.  
 
Overall, we saw that chemotherapy was effective as a first-line therapy but for 
relapse patients resistant to chemotherapeutics, understanding the behaviour of 
subclonal responses to targeted therapies will provide us insights on the impact 
of targeted therapies on targeted subclones which could be missed when response 




2. MECHANISTIC INSIGHTS ON GENETIC 
HETEROGENEITY UNDERLYING DRUG RESPONSE 
AND RESISTANCE 
By tracking treatment responses of cancer subclones, we gained valuable insights 
on mechanisms underlying drug response or resistance. Of the six patients in 
Study I who received targeted therapies, we were able to hypothesize the 
underlying mechanism of drug resistance and sensitivity in five patients (Table 
1). For example, response to dasatinib-sunitinib-temsirolimus therapy in patient 
#600 was mediated by FLT3 mutations. Similarly, patient #1186 showed 
response to azacitidine-sunitinib combination therapy, sunitinib sensitivity was 
mediated by the presence of mutation in PDGFRB fusion and FLT3. Based on 
significant subclonal response of DNMT3A, FLT3 and NPM1 mutated subclones 
to therapy, we hypothesise these mutations were underlying azacitidine 
sensitivity. Mutations in DNMT3A have been reported to sensitize patients to 
hypomethylating agents.130,131 Intrinsic resistance of patient #3443 and acquired 
resistance in #784 could also be explained based on their subclonal profiles.  In 
patient #3443 we identified loss of NF1 gene at diagnosis and first relapse which 
explains the intrinsic resistance of this patient to cytarabine-based therapy.132-134 
Subsequently, the patient relapsed with an additional loss of NF1 gene copy and 
deletion in DCK gene, providing mechanistic explanations to the observed 
resistances towards cytarabine- and subsequent ruxolitinib-trametinib -based 





Table 1: Mechanistic insights on drug-gene interactions 
 
In Study III, by integrating drug response and subclonal information from PDCs 
we identified subgroups of drugs that were likely to work on specific subclones. 
We identified a subgroup of drugs that were responsive in all PDCs that 
correspond to early mutations shared among the primary and metastatic sites. 
PDCs with shared mutations showed distinct drug response profiles that 
correlated with the genetic heterogeneity. Further, site-specific drug responses 
were observed for the PDCs, which in some cases correlated with the unique 
mutations identified in the site. Overall, we observed intra-tumor heterogeneity 
not just in the genetic composition but also in drug responsiveness.  
 
Taken together, we showed how tracking of subclonal architecture with treatment 
response could give mechanistic and pharmacogenomics insights on drug 
sensitivities and resistances. By inferring subclone-based responses, we can 
design intelligent therapeutic combinations that target multiple subclones, 
achieve longer remissions and prevent relapses or metastasis.  
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3. LESSONS LEARNT FROM PERSONALIZED 
TREATMENT OF PATIENTS 
Personalizing patient treatment with the aim to achieve greater impact and 
survival benefits has its advantages and limitations. In our individualized 
medicine program, involving clinical translation of DSRT and genome 
sequencing data in AML and RCC, we have gained better understanding on why 
and how some therapies could fail. Here I present my perspective of the lessons 
learnt from personalizing cancer therapy for patients.  
 
Temporal and Spatial tumor sampling: Acquiring and analyzing of multiple 
tumor samples from diagnosis to later relapses, metastasis and specifically before 
and after therapy forms the most important basis for implementing personalized 
therapy and monitoring its benefit. Taking tumor samples from multiple sites is 
necessary to gain a comprehensive estimation of intra-tumor heterogeneity while 
reducing sampling bias. We observed this effect to be more profound in solid 
tumors such as RCC than in AML, where the genetic heterogeneity between 
multiple sites was not as significant as in solid tumors. Secondly, given that 
clonal evolution of cancers is common, temporal sampling of the tumor should 
be part of any personalized medicine strategy. We showed in our studies how 
temporal sampling of tumor enabled us to monitor therapy response at subclone 
level and to gain understanding of the therapy responses, which differed from 
standard ways to measure clinical response in patients.  
 
As discussed earlier, tumors evolve in response to therapy and by studying 
responses of subclones from samples taken before, after and during therapy we 
could identify the source of drug-resistant subclones seen at relapse, differential 
response of subclones to chemo and targeted therapies and mechanisms 
underlying drug sensitivities and resistance. Therefore, spatial and temporal 
sampling of tumor is necessary to understand the nature of cancer in an individual 
patient before designing personalized treatment options. Although it might not 
be clinically feasible in all cancers to obtain patient biopsies frequently, 
approaches such as liquid biopsies can be considered. However, the measurement 
of blood clonal composition in liquid or solid tumors represents a summary of 
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the responses at multiple sites, and it cannot reveal the same subclonal data as 
biopsies from individual sites. 
 
Adapting and developing methodologies: Technological improvements in 
sequencing, new discoveries such as CRISPR-Cas9 genome editing technology 
and other biological advancements result in accumulation of new, large-scale 
data. In the context of personalized medicine, new insights on cancer biology, 
drug discoveries, and therapy regimens call for an improved method to integrate 
large-scale data to benefit a single patient. For example, we adapted an existing 
deep-sequencing approach to enhance rare variant calling. Similarly, new tools 
have been developed to identify subclonal composition, driver mutations, intra-
tumoral heterogeneity and inferring cancer –cell lineage to expand our 
understanding of cancer biology while addressing the dynamic nature of 
evolution. With the ever-increasing amount of data that is generated, new 
analytical methods to optimally utilize the data and integrate multiple data sets 
are required.  
 
 
Why do some patients respond to treatment while others do not?  Clinical 
translation of research findings does not always yield the desired benefit. While 
translating our findings to clinical use in patient treatment, we saw examples of 
ex vivo responses correlating with patient response as well as frequent cases 
where ex vivo results did not translate in vivo. There are many factors that 
contribute to the failure of translating ex vivo responses in vivo. One of the major 
factors being the fact that cells in culture do not replicate the tumor 
microenvironment resulting in drug responses that cannot be translated clinically. 
In one such study, finding from our ISM platform showed how cells cultured in 
bone marrow stroma-derived conditional media showed significantly reduced 
sensitivity of BCL2 inhibitors and increased sensitivity to JAK inhibitors in 
comparison to standard cell culture media.138 The study highlights the impact 
micro-environment can have on drug sensitivities and the importance of cell 
culture media conditions in mimicking in vivo conditions.  
Another crucial factor that impacts the clinical translation of targeted therapies is 
the clonal and subclonal composition of the patient. Given the heterogeneity of 
cancer, it is critical to identify if the targeted genes are clonal or subclonal. If the 
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targeted gene is subclonal, the major clone present in the tumor is not eradicated. 
Also, as shown in our study and other previous reports106,107,139, subclones that 
are in low frequency can emerge to dominate at relapse therefore underscoring 
the importance of targeting multiple subclones.  
 
Retrospective versus prospective analysis: Time is a crucial factor for 
translating personalized molecular data to the clinic, especially in advanced, fast 
progressing cancers. In order to enable translation of drug response, genomic, 
epigenomic, proteomic and other related patient data, it is critical to generate, 
analyze and assimilate these data into meaningful clinical recommendations in a 
matter of days and at the level of n=1, without the ability to use classical statistical 
approaches. Therefore, in the majority of our cases clinical translation in chemo-
refractory AML has been based on ex vivo drug response data that is generated 
and interpreted within 3-4 days. Current genomic sequencing analysis is not as 
rapid to be available along with drug response data, but the falling costs and 
improved sequencing technologies will enable faster generation and analysis of 
data in near future. Therefore, analysis of clonal evolution, heterogeneity and 
subclonal responses to therapy is currently done retrospectively rather than 
prospectively. Although this might not benefit the patient in question, we gain 
valuable insights on subclonal dynamics in response to therapy, correlation 
between subclone and drug responses, mechanistic insights on therapy that will 
undoubtedly benefit future patient care and drug discoveries. It is important to 
deliberate on strategies that can enable prospective analysis of subclonal 
emergence and therapy that will help us target clonal evolution and heterogeneity 
thereby preventing relapse or metastasis.  Therefore, both retrospective and 
prospective analysis of clonal evolution and heterogeneity will have great impact 
on cancer treatment both at personalized and cohort level.  
 
4. NEXT STEPS: TARGETING CLONAL 
HETEROGENEITY AND EVOLUTION 
The first step in solving a complexity is recognizing and understanding the extent 
of it. Our understanding of clonal evolution and heterogeneity of cancers has 
rapidly increased in the last eight years with the application of massively parallel 
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sequencing divulgating cancer evolution and heterogeneity from spatially and 
temporally acquired tumor samples. By studying the impact of treatment on 
subclones and vice versa, we can redefine our personalized therapy and drug 
development strategies to target clonal evolution and heterogeneity. We are now 
starting to piece together the puzzle of cancer. Recent interesting studies have 
shown how cancers can evolve in non-Darwinian fashion, wherein drug resistant 
cells are not developed based on selection pressure but in a Lamarckian fashion 
wherein the drug resistant phenotype is induced and enhanced by multiple 
processes.140,141 
 
Cancer is basically a composition of cells with extraordinary proliferating 
capacity that have evaded all known checkpoints to control the growth. In 
addition, it evolves dynamically by acquiring new mutations and adapts for 
survival. As stated by Mel Greaves, if we were to live long enough, we (all) will 
eventually develop “covert” cancer.142 In the light of evidence pointing to the 
extent of cancer heterogeneity and evolution underlying drug resistance, and the 
failure of both chemo and targeted drugs in achieving cancer cure, the question 
we need to ask is; can cancer be cured? Maybe this is not possible in all cases.  
 
Therefore, many recent strategies rethinking the way to treat cancer are evolving. 
For instance, adaptive therapy proposed by Gatenby et al. advocates that 
eliminating all cancer cells eventually leads to emergence of resistant clones. 
Whereas, maintaining a stable cancer cell population causes less heterogeneity 
and competing evolution that could result in long-term survival. The approach 
essentially limits the heterogeneity of cancer subclones by eliminating selective 
pressures and maintaining drug responsive cell populations. The authors have 
shown evidence of adaptive therapy achieving long-term survival in ovarian 
cancer mice models injected with carboplatin therapy in multiple doses based on 
tumor size, wherein the dosage was reduced if the tumor reduced in size. The 
adaptive therapy strategy has its main advantage in addressing the evolutionary 
complexity of tumors. Although clinical adoption of this strategy might be 
challenging where appropriate estimation of treatment dosage versus tumor 




Similarly, other methods have been proposed to address tumor heterogeneity and 
evolution while treating cancer. Swanton et al. proposed the targeting of trunk 
antigens, which would result in higher causality of cancer cells rather than aiming 
for antigens targeting subclones that constitute the branches. One such approach 
involves identifying vulnerabilities acquired by cancer cells after developing 
resistance to drug A. Drug B that is sensitive in the new cancer might select for 
the pre-existing minor subclone that was response to drug A. The method 
basically involves exploiting vulnerabilities while balancing for resistance.  
 
All these methods have their benefits and drawbacks, but the evolving treatment 
strategies will lead way to better treatment and management of cancer. Recent 
advances in immunotherapies for cancer, especially in leukemias are very 
promising. The approach of de-bulking the tumor initially with chemotherapy or 
targeted therapy and subsequently using immunotherapy to prevent future 
recurrence has its merit in combining existing treatment regimens with novel 
immunotherapies.143,144 The growing idea of maintaining cancer as a chronic 
disease while reducing cancer cell heterogeneity is another way forward. Further 
studies on the applicability and impact of this strategy are required. Overall, 
personalized medicine strategy that takes into consideration clonal evolution and 
heterogeneity will provide us valuable insights on treating cancer at both 















“It is not our part to master all the tides of the world, but to do what is in us for 
the succour of those years wherein we are set, uprooting the evil in the fields that 
we know, so that those who live after may have clean earth to till.” 
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